Abstract

Background. The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens. Materials and Methods. A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken. Conclusions. There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients.

Highlights

  • The peritoneal surface is an established failure site for digestive and gynecological malignancies as well as the primary location for some tumors [1,2,3,4,5,6,7]

  • This paper aims to clarify the pharmacologic base underlying these treatment regimens

  • One should keep in mind that the equation permits calculation of the pharmacokinetic advantage, the model does not predict the actual penetration of the cancer chemotherapy drug into the tissue or tumor nodule [30]

Read more

Summary

Background

The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens. A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken. There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients

Introduction
Dose Intensification
Drugs Used in Perioperative Cancer Chemotherapy Protocols
Pharmacologic Variables in Perioperative Chemotherapy
Pharmacologic Controversies
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call